featured
UCART19, a First-in-Class Allogeneic Anti-CD19 CAR T-Cell Therapy, for Adults With Relapsed/Refractory B-ALL
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Haematology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial
Lancet Haematol 2022 Nov 01;9(11)e833-e843, R Benjamin, N Jain, MV Maus, N Boissel, C Graham, A Jozwik, D Yallop, M Konopleva, MJ Frigault, T Teshima, K Kato, F Boucaud, S Balandraud, A Gianella-Borradori, F Binlich, I Marchiq, S Dupouy, M Almena-Carrasco, M Pannaux, S Fouliard, E Brissot, M MohtyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.